In an effort to lower the risk of atrial fibrillation recurrence following ablation procedures, Acutus developed mapping technology. The business promoted its non-contact mapping method as a superior match for arrhythmias that are complicated or unstable, such as atrial fibrillation, but it has had trouble turning its faith in the technique into profits.
In 2022, Acutus’ left-heart access transseptal crossing business was bought by Medtronic, which paid $50 million up front and a further $20 million before the year ended. As per the arrangement, Acutus retained the producer of the devices, but Medtronic became their sole distributor.